poisar

Stocks · News reference

Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff Threat

BenzingaVandana Singh

Dr. Reddy's (RDY) stock drops after missing Q1 FY27 earnings & revenue estimates. Semaglutide issues & Trump tariff plans weigh on shares.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncResearchandmarkets.Com

    Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth

    The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.

  2. BenzingaBenzinga Insights

    Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript

    Dr Reddy's Laboratories (NYSE:RDY) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial